- Home
- SRFM vs APLT Comparison
SRFM vs APLT Comparison
Compare SRFM & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- APLT
- Stock Information
- Founded
- SRFM 2011
- APLT 2016
- Country
- SRFM United States
- APLT United States
- Employees
- SRFM N/A
- APLT N/A
- Industry
- SRFM Transportation Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- APLT Health Care
- Exchange
- SRFM Nasdaq
- APLT Nasdaq
- Market Cap
- SRFM 191.9M
- APLT 178.6M
- IPO Year
- SRFM 2023
- APLT 2019
- Fundamental
- Price
- SRFM $5.42
- APLT $1.05
- Analyst Decision
- SRFM Buy
- APLT Buy
- Analyst Count
- SRFM 4
- APLT 5
- Target Price
- SRFM $5.75
- APLT $4.13
- AVG Volume (30 Days)
- SRFM 2.7M
- APLT 11.8M
- Earning Date
- SRFM 11-13-2025
- APLT 11-06-2025
- Dividend Yield
- SRFM N/A
- APLT N/A
- EPS Growth
- SRFM N/A
- APLT N/A
- EPS
- SRFM N/A
- APLT N/A
- Revenue
- SRFM $107,372,000.00
- APLT $121,000.00
- Revenue This Year
- SRFM N/A
- APLT N/A
- Revenue Next Year
- SRFM $18.06
- APLT $5,931.24
- P/E Ratio
- SRFM N/A
- APLT N/A
- Revenue Growth
- SRFM N/A
- APLT N/A
- 52 Week Low
- SRFM $1.50
- APLT $0.30
- 52 Week High
- SRFM $9.91
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- SRFM 66.73
- APLT 66.45
- Support Level
- SRFM $4.82
- APLT $0.56
- Resistance Level
- SRFM $5.32
- APLT $1.32
- Average True Range (ATR)
- SRFM 0.34
- APLT 0.17
- MACD
- SRFM 0.11
- APLT 0.05
- Stochastic Oscillator
- SRFM 98.39
- APLT 73.60
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.